Novo presents detailed CV data for Victoza

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) reported detailed data from the LEADER CV outcomes trial comparing diabetes drug Victoza liraglutide plus standard of care vs. placebo plus SOC. In March, the company said Victoza met LEADER's primary endpoint of significantly reducing cardiovascular risk versus SOC (see BioCentury Extra, March 4).

The glucagon-like peptide-1 (GLP-1) analog reduced CV risk by 13% vs. placebo plus SOC (HR=0.87; 95% CI: 0.78, 0.97; p<0.001 for non-inferiority and p=0.01 for superiority), as measured by the composite primary endpoint of time to first occurrence of CV death, non-fatal myocardial infarction or non-fatal stroke. ...